Clinical Trials
9
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease
- Conditions
- Fabry Disease
- Interventions
- Biological: Fabagal® (Agalsidase beta)Drug: Active comparator (Agalsidase beta)
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- ISU Abxis Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06081062
- Locations
- 🇰🇷
Seoul Asan Center, Seoul, Songpa-gu, Korea, Republic of
🇵🇭Philippine General Hospital, Manila, Philippines
🇵🇭St.Luke's Medical Center, Manila, Philippines
A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- ISU Abxis Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT04787887
- Locations
- 🇦🇺
Scientia Clinical Research Limited, Randwick, New South Wales, Australia
Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- ISU Abxis Co., Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT03552406
- Locations
- 🇰🇷
Kosin University Gospel Hospital, Busan, Korea, Republic of
🇰🇷Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients
- Conditions
- Hemophilia B
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- ISU Abxis Co., Ltd.
- Target Recruit Count
- 11
- Registration Number
- NCT03186677
- Locations
- 🇰🇷
Eulji University Hospital, Daejeon, Korea, Republic of
🇰🇷Pusan National Univesity Hospital, Pusan, Korea, Republic of
🇰🇷Yonsei University Medical Center, Seoul, Korea, Republic of
Exploratory P2 Trial to Evaluate Efficacy and Safety of Clotinab® (Abciximab) in Acute MI Patients
- Conditions
- Acute Myocardial Infarction
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- ISU Abxis Co., Ltd.
- Target Recruit Count
- 146
- Registration Number
- NCT03087539
- Locations
- 🇰🇷
Chonnam National University, Gwangju, Chonnam, Korea, Republic of
- Prev
- 1
- 2
- Next